DE60329274D1 - Kontrastmittel und verfahren zum imaging von naaldase oder psma - Google Patents
Kontrastmittel und verfahren zum imaging von naaldase oder psmaInfo
- Publication number
- DE60329274D1 DE60329274D1 DE60329274T DE60329274T DE60329274D1 DE 60329274 D1 DE60329274 D1 DE 60329274D1 DE 60329274 T DE60329274 T DE 60329274T DE 60329274 T DE60329274 T DE 60329274T DE 60329274 D1 DE60329274 D1 DE 60329274D1
- Authority
- DE
- Germany
- Prior art keywords
- psma
- imaging
- methods
- naaldase
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 title abstract 3
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 title abstract 3
- 238000003384 imaging method Methods 0.000 title abstract 3
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 210000000056 organ Anatomy 0.000 abstract 3
- 108090000369 Glutamate Carboxypeptidase II Proteins 0.000 abstract 2
- 102100020995 Putative N-acetylated-alpha-linked acidic dipeptidase Human genes 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 150000003672 ureas Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
- C07C275/20—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
- C07C275/24—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0032—Methine dyes, e.g. cyanine dyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0052—Small organic molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
- C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
- C07C323/59—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton with acylated amino groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F11/00—Compounds containing elements of Groups 6 or 16 of the Periodic System
- C07F11/005—Compounds containing elements of Groups 6 or 16 of the Periodic System compounds without a metal-carbon linkage
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/62—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving urea
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus for radiation diagnosis, e.g. combined with radiation therapy equipment
- A61B6/50—Clinical applications
- A61B6/508—Clinical applications for non-human patients
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US34748702P | 2002-01-10 | 2002-01-10 | |
PCT/US2003/000680 WO2003060523A1 (en) | 2002-01-10 | 2003-01-10 | Imaging agents and methods of imaging naaladase of psma |
Publications (1)
Publication Number | Publication Date |
---|---|
DE60329274D1 true DE60329274D1 (de) | 2009-10-29 |
Family
ID=23363898
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60329274T Expired - Lifetime DE60329274D1 (de) | 2002-01-10 | 2003-01-10 | Kontrastmittel und verfahren zum imaging von naaldase oder psma |
Country Status (11)
Country | Link |
---|---|
US (4) | US7408079B2 (de) |
EP (1) | EP1472541B1 (de) |
AT (1) | ATE443260T1 (de) |
AU (1) | AU2003205077A1 (de) |
CA (1) | CA2473289C (de) |
DE (1) | DE60329274D1 (de) |
DK (1) | DK1472541T3 (de) |
ES (1) | ES2338414T3 (de) |
PT (1) | PT1472541E (de) |
SI (1) | SI1472541T1 (de) |
WO (1) | WO2003060523A1 (de) |
Families Citing this family (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6528499B1 (en) | 2000-04-27 | 2003-03-04 | Georgetown University | Ligands for metabotropic glutamate receptors and inhibitors of NAALADase |
EP1448588A4 (de) | 2001-10-23 | 2006-10-25 | Psma Dev Company L L C | Psma-antikörper und proteinmultimere |
US20050215472A1 (en) | 2001-10-23 | 2005-09-29 | Psma Development Company, Llc | PSMA formulations and uses thereof |
WO2007001448A2 (en) * | 2004-11-04 | 2007-01-04 | Massachusetts Institute Of Technology | Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals |
WO2007070682A2 (en) | 2005-12-15 | 2007-06-21 | Massachusetts Institute Of Technology | System for screening particles |
WO2008105773A2 (en) | 2006-03-31 | 2008-09-04 | Massachusetts Institute Of Technology | System for targeted delivery of therapeutic agents |
US20110052697A1 (en) * | 2006-05-17 | 2011-03-03 | Gwangju Institute Of Science & Technology | Aptamer-Directed Drug Delivery |
WO2007150030A2 (en) * | 2006-06-23 | 2007-12-27 | Massachusetts Institute Of Technology | Microfluidic synthesis of organic nanoparticles |
WO2008019142A2 (en) * | 2006-08-04 | 2008-02-14 | Massachusetts Institute Of Technology | Oligonucleotide systems for targeted intracellular delivery |
WO2008058192A2 (en) * | 2006-11-08 | 2008-05-15 | Molecular Insight Pharmaceuticals, Inc. | Heterodimers of glutamic acid |
US20100303723A1 (en) * | 2006-11-20 | 2010-12-02 | Massachusetts Institute Of Technology | Drug delivery systems using fc fragments |
WO2008098165A2 (en) | 2007-02-09 | 2008-08-14 | Massachusetts Institute Of Technology | Oscillating cell culture bioreactor |
EP2144600A4 (de) * | 2007-04-04 | 2011-03-16 | Massachusetts Inst Technology | Poly (aminsäure)-zielmoleküle |
CA2926573C (en) * | 2007-06-26 | 2018-08-28 | The Johns Hopkins University | Labeled inhibitors of prostate specific membrane antigen (psma), biological evaluation, and use as imaging agents |
AU2015203742B2 (en) * | 2007-06-26 | 2016-12-01 | The Johns Hopkins University | Labeled inhibitors of prostate specific membrane antigen (psma), biological evaluation, and use as imaging agents |
EP3858347A3 (de) | 2007-08-17 | 2021-12-01 | Purdue Research Foundation | Psma-bindungsliganden-linker-konjugate und anwendungsverfahren |
DK2644192T3 (en) | 2007-09-28 | 2017-06-26 | Pfizer | Cancer cell targeting using nanoparticles |
ES2627233T3 (es) | 2007-10-12 | 2017-07-27 | Massachusetts Institute Of Technology | Nanotecnología de vacunas |
US8562945B2 (en) | 2008-01-09 | 2013-10-22 | Molecular Insight Pharmaceuticals, Inc. | Technetium- and rhenium-bis(heteroaryl) complexes and methods of use thereof |
ES2556629T3 (es) | 2008-05-13 | 2016-01-19 | Yale University | Moléculas pequeñas quiméricas para el reclutamiento de anticuerpos contra células cancerosas |
US8852630B2 (en) | 2008-05-13 | 2014-10-07 | Yale University | Chimeric small molecules for the recruitment of antibodies to cancer cells |
CA2728176C (en) | 2008-06-16 | 2017-07-04 | Bind Biosciences, Inc. | Drug loaded polymeric nanoparticles and methods of making and using same |
ES2721850T3 (es) * | 2008-06-16 | 2019-08-05 | Pfizer | Nanopartículas poliméricas terapéuticas que comprenden alcaloides vinca y procedimientos de fabricación y uso de las mismas |
US8613951B2 (en) | 2008-06-16 | 2013-12-24 | Bind Therapeutics, Inc. | Therapeutic polymeric nanoparticles with mTor inhibitors and methods of making and using same |
US8591905B2 (en) | 2008-10-12 | 2013-11-26 | The Brigham And Women's Hospital, Inc. | Nicotine immunonanotherapeutics |
US8277812B2 (en) | 2008-10-12 | 2012-10-02 | Massachusetts Institute Of Technology | Immunonanotherapeutics that provide IgG humoral response without T-cell antigen |
US8563041B2 (en) | 2008-12-12 | 2013-10-22 | Bind Therapeutics, Inc. | Therapeutic particles suitable for parenteral administration and methods of making and using same |
JP2012512175A (ja) | 2008-12-15 | 2012-05-31 | バインド バイオサイエンシズ インコーポレイテッド | 治療薬を徐放するための長時間循環性ナノ粒子 |
LT3222617T (lt) | 2009-03-19 | 2022-10-25 | The Johns Hopkins University | Psma nukreipti junginiai ir jų naudojimas |
US20180009767A9 (en) | 2009-03-19 | 2018-01-11 | The Johns Hopkins University | Psma targeted fluorescent agents for image guided surgery |
AU2010260195B2 (en) | 2009-06-15 | 2014-11-20 | Molecular Insight Pharmaceuticals, Inc. | Process for production of heterodimers of glutamic acid |
EP2456757B1 (de) | 2009-07-22 | 2019-05-01 | The Board of Trustees of the University of Illionis | Hdac-hemmer und therapieverfahren dafür |
TR201906255T4 (tr) | 2009-12-11 | 2019-05-21 | Pfizer | Terapötik partiküllerin liyofilize edilmesine yönelik stabil formülasyonlar. |
JP5965844B2 (ja) | 2009-12-15 | 2016-08-10 | バインド セラピューティックス インコーポレイテッド | 高いガラス転移温度または高分子量のコポリマーを有する治療用ポリマーナノ粒子組成物 |
EP2338892A1 (de) | 2009-12-18 | 2011-06-29 | Bayer Schering Pharma Aktiengesellschaft | Prostataspezifische Membranantigen-Inhibitoren |
US9951324B2 (en) | 2010-02-25 | 2018-04-24 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
USRE47009E1 (en) | 2011-02-01 | 2018-08-28 | The Children's Hospital Of Philadelphia | HDAC inhibitors and therapeutic methods using the same |
EP3505192A1 (de) * | 2011-08-05 | 2019-07-03 | Molecular Insight Pharmaceuticals, Inc. | Radioaktiv markierte prostataspezifische membranantigen-inhibitoren |
US20130116404A1 (en) | 2011-11-08 | 2013-05-09 | Case Western Reserve University | Targeted non-invasive imaging probes of egfr expressing cells |
EP2785712B1 (de) * | 2011-11-30 | 2019-05-01 | The Johns Hopkins University | Homomultivalente und heteromultivalente inhibitoren des prostataspezifischen membranantigens (pmsa) und verwendungen davon |
CA2860504A1 (en) | 2012-01-06 | 2013-07-11 | Molecular Insight Pharmaceuticals | Metal complexes of poly(carboxyl)amine-containing ligands having an affinity for carbonic anhydrase ix |
SI2895156T1 (sl) | 2012-09-17 | 2019-08-30 | Pfizer Inc. | Postopek za pripravo terapevtskih nanodelcev |
SG10201706618UA (en) * | 2012-11-15 | 2017-09-28 | Endocyte Inc | Conjugates for treating diseases caused by psma expressing cells |
PL2943227T3 (pl) | 2013-01-14 | 2018-02-28 | Molecular Insight Pharmaceuticals, Inc. | Triazynowe radiofarmaceutyki i środki do obrazowania radiologicznego |
KR101947053B1 (ko) | 2013-10-18 | 2019-02-12 | 도이체스 크렙스포르슝스첸트룸 | 전립선 특이적 막 항원(psma)의 표지된 억제제, 조영제로서의 이의 용도 및 전립선암 치료용 약제 |
DK3511019T3 (da) | 2014-03-14 | 2020-10-26 | Pfizer | Terapeutiske nanopartikler omfattende et terapeutisk middel og fremgangsmåder til fremstilling og anvendelse deraf |
WO2016065142A2 (en) | 2014-10-22 | 2016-04-28 | The Johns Hopkins University | New scaffolds and multifunctional intermediates for imaging psma and cancer therapy |
US10188759B2 (en) | 2015-01-07 | 2019-01-29 | Endocyte, Inc. | Conjugates for imaging |
US20180338910A1 (en) * | 2015-01-09 | 2018-11-29 | The Johns Hopkins University | Intranasal administration of glutamate carboxypeptidase (gcp-ii) inhibitors |
US10869940B2 (en) | 2015-06-12 | 2020-12-22 | The Board Of Trustees Of The Leland Stanford Junior University | Targeted photoacoustic compounds, formulations, and uses thereof |
WO2017040564A1 (en) | 2015-09-03 | 2017-03-09 | The Board Of Trustees Of The University Of Illinois | Hdac inhibitors and therapeutic methods using the same |
AU2016333334B2 (en) | 2015-09-30 | 2019-07-25 | Deutsches Krebsforschungszentrum | 18F-tagged inhibitors of prostate specific membrane antigen (PSMA) and their use as imaging agents for prostate cancer |
US10688200B2 (en) | 2015-12-31 | 2020-06-23 | Five Eleven Pharma Inc. | Urea-based prostate specific membrane antigen (PSMA) inhibitors for imaging and therapy |
US10456394B2 (en) | 2016-02-16 | 2019-10-29 | The Board Of Trustees Of The University Of Illinois | Tetrahydroquinoline substituted hydroxamic acids as selective histone deacetylase 6 inhibitors |
US20170296679A1 (en) | 2016-04-18 | 2017-10-19 | Intuitive Surgical Operations, Inc. | Compositions of Near IR Closed Chain, Sulfo-Cyanine Dyes and Prostate Specific Membrane Antigen Ligands |
EP3600295A4 (de) | 2017-03-29 | 2021-04-07 | The George Washington University, A Congressionally Chartered Not-For-Profit Corporation | Isoxazolhydroxamsäuren als histondeacetylase-6-inhibitoren |
CN110730660A (zh) | 2017-04-26 | 2020-01-24 | 伊利诺伊大学评议会 | Nrf和HIF活化剂/HDAC抑制剂和使用其的治疗方法 |
KR20200141439A (ko) | 2018-02-06 | 2020-12-18 | 더 존스 홉킨스 유니버시티 | 암 방사선 치료를 위한 psma 표적 방사성 할로겐화 우레아-폴리아미노카복실레이트 |
WO2019183633A1 (en) | 2018-03-23 | 2019-09-26 | Case Western Reserve Univeristy | Psma targeted conjugate compounds and uses thereof |
KR20200043115A (ko) * | 2018-10-17 | 2020-04-27 | 고려대학교 세종산학협력단 | 전립선암의 진단과 치료를 위한 전립선 특이 막 항원 저해제 및 이를 포함하는 전립선암 진단 및 치료용 약학 조성물 |
EP3958916A4 (de) * | 2019-04-26 | 2023-08-09 | Five Eleven Pharma Inc. | Inhibitoren des prostataspezifischen membranantigens (psma) als diagnostische und radionuklidtherapeutische mittel |
EP4244216A1 (de) | 2020-11-12 | 2023-09-20 | ABX Advanced Biochemical Compounds GmbH | Liganden des prostata-spezifischen membranantigens (psma) mit heteroaromatischen linker-bausteinen |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5962521A (en) | 1997-04-04 | 1999-10-05 | Guilford Pharmaceuticals Inc. | Hydroxamic acid derivatives |
BE1012622A3 (fr) | 1999-04-21 | 2001-01-09 | Solvay | Procede pour la separation d'enantiomeres et reactif enantiopur. |
US6528499B1 (en) * | 2000-04-27 | 2003-03-04 | Georgetown University | Ligands for metabotropic glutamate receptors and inhibitors of NAALADase |
DE60020962T2 (de) * | 1999-04-28 | 2006-05-24 | Georgetown University | Liganden für metabotropische Glutamat-Rezeptoren |
AU2001249608A1 (en) | 2000-03-28 | 2001-10-08 | Beth Israel Deaconess Medical Center | Bladder cancer-specific peptides for diagnosis and therapy |
-
2003
- 2003-01-10 EP EP03703745A patent/EP1472541B1/de not_active Expired - Lifetime
- 2003-01-10 AT AT03703745T patent/ATE443260T1/de active
- 2003-01-10 WO PCT/US2003/000680 patent/WO2003060523A1/en not_active Application Discontinuation
- 2003-01-10 AU AU2003205077A patent/AU2003205077A1/en not_active Abandoned
- 2003-01-10 PT PT03703745T patent/PT1472541E/pt unknown
- 2003-01-10 US US10/340,864 patent/US7408079B2/en not_active Expired - Lifetime
- 2003-01-10 SI SI200331710T patent/SI1472541T1/sl unknown
- 2003-01-10 CA CA2473289A patent/CA2473289C/en not_active Expired - Fee Related
- 2003-01-10 DE DE60329274T patent/DE60329274D1/de not_active Expired - Lifetime
- 2003-01-10 DK DK03703745.4T patent/DK1472541T3/da active
- 2003-01-10 ES ES03703745T patent/ES2338414T3/es not_active Expired - Lifetime
-
2008
- 2008-05-22 US US12/154,445 patent/US8227634B2/en not_active Expired - Lifetime
-
2012
- 2012-06-29 US US13/537,789 patent/US20120276007A1/en not_active Abandoned
-
2014
- 2014-05-22 US US14/285,282 patent/US20150079001A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2003060523A1 (en) | 2003-07-24 |
US7408079B2 (en) | 2008-08-05 |
CA2473289A1 (en) | 2003-07-24 |
SI1472541T1 (sl) | 2010-12-31 |
EP1472541A1 (de) | 2004-11-03 |
PT1472541E (pt) | 2009-12-21 |
ES2338414T3 (es) | 2010-05-07 |
US8227634B2 (en) | 2012-07-24 |
US20090117042A1 (en) | 2009-05-07 |
CA2473289C (en) | 2014-07-29 |
DK1472541T3 (da) | 2010-01-25 |
EP1472541B1 (de) | 2009-09-16 |
US20150079001A1 (en) | 2015-03-19 |
AU2003205077A1 (en) | 2003-07-30 |
US20120276007A1 (en) | 2012-11-01 |
US20040054190A1 (en) | 2004-03-18 |
ATE443260T1 (de) | 2009-10-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60329274D1 (de) | Kontrastmittel und verfahren zum imaging von naaldase oder psma | |
ATE527552T1 (de) | Mr-darstellungsverfahren zur diskriminierung zwischen gesundem und tumorgewebe | |
TW200600087A (en) | Methods and compositions for treating amyloid-related diseases | |
WO2003087831A3 (en) | Proteins involved in breast cancer | |
MXPA05013977A (es) | Metodos y composiciones para tratar enfermedades relacionadas con amiloide. | |
ATE483976T1 (de) | Gfats als modifikatoren des p53-wegs und verwendungsverfahren | |
CY1112055T1 (el) | Συνθεσεις και μεθοδοι για την διαγνωση και θεραπευτικη αγωγη ογκου πνευμονα | |
DK3059322T3 (da) | Genekspressionsmarkører for brystcancerprognose | |
ATE349446T1 (de) | Amyloid plaque aggregationshemmer und diagnostische bilderzeugungsmittel | |
BR0315689A (pt) | Alvo para terapia de dano cognitivo | |
DE602005026866D1 (de) | Vewendung von dreidimensionalem kultiviertem gewebe zur behandlung von kongestivem herzversagen | |
BR0306715A (pt) | Métodos para diagnóstico e tratamento de tumores | |
NO20053903D0 (no) | Nukleotidlipidesterderivater. | |
HK1056692A1 (en) | Proteins | |
DE60127951D1 (de) | Kleine technetium-99m und rhenium markierte mittel und verfahren zum tumor-imaging | |
ATE393917T1 (de) | Identifikation von therapeutische verbindungen. | |
WO2004043380A8 (en) | Small technetium-99m and rhenium labeled agents and methods for imaging tissues, organs and tumors | |
HK1074840A1 (en) | Novel dithiolopyrrolones with therapeutic activity | |
DK1359943T3 (da) | Biotinderivater og deres konjugater med chelateringsmidler | |
DE60030270D1 (de) | Fettsaure analoge zur diagnose von kranzarterie erkrankungen | |
ATE529536T1 (de) | Verfahren zur identifizierung und behandlung von komplexe karyotypen zeigenden individuen | |
DE602004022423D1 (de) | Hemmung der s6-kinase-aktivität zur behandlung von insulinresistenz | |
ATE364180T1 (de) | Screeningverfahren mit bnpi und dnpi | |
DE602004006566D1 (de) | Verfahren zur Diagnose und Behandlung von Metastasen und dafür nützliche Zusammensetzung | |
ATE469175T1 (de) | Prkcs als modifikatoren des beta catenin pfads und anwendungsverfahren |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8327 | Change in the person/name/address of the patent owner |
Owner name: GEORGETOWN UNIVERSITY, WASHINGTON, D.C., US Owner name: THE JOHNS HOPKINS UNIVERSITY, BALTIMORE, MD., US |
|
8364 | No opposition during term of opposition | ||
R119 | Application deemed withdrawn, or ip right lapsed, due to non-payment of renewal fee |
Ref document number: 1472541 Country of ref document: EP |
|
R074 | Re-establishment allowed |
Ref document number: 1472541 Country of ref document: EP |